Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Trump Says Iran Ceasefire ‘On Life Support’ as Oil Prices Surge Above $104 
US Auto Industry Urges Trump to Block Chinese EV Market Access 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Goldman Sachs Delays Fed Rate Cut Forecast to 2026 Amid Rising Inflation Concerns 
FDA Warns Novo Nordisk Over Misleading Ozempic Ad Claims 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Nike Tariff Refund Lawsuit Sparks Consumer Backlash Over Price Increases 
China Inflation Jumps as Iran Conflict Drives Energy Costs Higher 
South Korea Central Bank Signals Inflation Concerns as Oil Prices Surge 
Asian Stocks Slip as Korea’s KOSPI Tumbles Amid Iran Conflict and Chip Sector Profit-Taking 
China Car Sales Drop Again as EV Export Growth Surges in April 
Trump Rejects Iran Proposal as Strait of Hormuz Crisis Pushes Oil Prices Higher 
TikTok Nears $400 Million Settlement With Trump Administration Over Child Privacy Lawsuit 
K+S Raises 2026 Earnings Outlook After Strong Q1 Results 
Dollar Gains on Safe-Haven Demand as Iran Tensions and Inflation Data Loom 
SK Bioscience has applied for conditional approval for the use of SKY Covione, a COVID-19 vaccine, with the European Medicines Agency (EMA).
SKY Covione, developed jointly by the biotech affiliate of SK Group and the Institute for Protein Design (IPD) at the University of Washington, is a synthetic vaccine considered safer than those originating from bacterial cultures.
The Bill & Melinda Gates Foundation provided funding for the product development.
According to Phase 3 clinical studies, the vaccine is significantly more immunogenic than the control vaccination Vaxzeria from AstraZeneca, according to SK Bioscience.
Extensive research in Phase 1 therapeutic trials showed that SKY Covione also induced a potent immune response against BA.1, of the Omicron variant family, when provided with booster shots.
The SK affiliate anticipates that the product will have a competitive advantage in the international market, which requires a consistent and stable supply of vaccines in the upcoming months.
Once it is added to the World Health Organization (WHO) Emergency Use List, it will be distributed to the global market through the COVID-19 Vaccines Global Access (COVAX) project, a global program created to enable equal access to COVID-19 vaccines.
According to data from the Korea Customs Service, Korea imported $2.35 billion worth of vaccines last year, a seven-fold rise from $340 million the year before.
